RU2015113746A - Замещенные сульфонамиды - Google Patents
Замещенные сульфонамиды Download PDFInfo
- Publication number
- RU2015113746A RU2015113746A RU2015113746A RU2015113746A RU2015113746A RU 2015113746 A RU2015113746 A RU 2015113746A RU 2015113746 A RU2015113746 A RU 2015113746A RU 2015113746 A RU2015113746 A RU 2015113746A RU 2015113746 A RU2015113746 A RU 2015113746A
- Authority
- RU
- Russia
- Prior art keywords
- trifluoromethyl
- fluoro
- acetamide
- amino
- ylmethyl
- Prior art date
Links
- 229940124530 sulfonamide Drugs 0.000 title 1
- 150000003456 sulfonamides Chemical class 0.000 title 1
- -1 —CHCF Chemical group 0.000 claims abstract 61
- 150000001875 compounds Chemical class 0.000 claims abstract 39
- 229910052801 chlorine Inorganic materials 0.000 claims abstract 13
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 13
- 150000003839 salts Chemical class 0.000 claims abstract 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 12
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 12
- 239000001257 hydrogen Substances 0.000 claims abstract 12
- 125000000217 alkyl group Chemical group 0.000 claims abstract 10
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims abstract 8
- 229910052805 deuterium Inorganic materials 0.000 claims abstract 8
- 229910052736 halogen Inorganic materials 0.000 claims abstract 8
- 150000002367 halogens Chemical class 0.000 claims abstract 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 7
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 7
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims abstract 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract 5
- 229910052794 bromium Inorganic materials 0.000 claims abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 4
- 150000002431 hydrogen Chemical class 0.000 claims abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 4
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims abstract 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims abstract 4
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims abstract 3
- 229910052799 carbon Inorganic materials 0.000 claims abstract 3
- 150000001721 carbon Chemical group 0.000 claims abstract 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract 3
- 125000002393 azetidinyl group Chemical group 0.000 claims abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 2
- 125000003566 oxetanyl group Chemical group 0.000 claims abstract 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims abstract 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract 2
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 claims abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 9
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 claims 6
- 208000027601 Inner ear disease Diseases 0.000 claims 6
- 208000002193 Pain Diseases 0.000 claims 6
- 208000003251 Pruritus Diseases 0.000 claims 6
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 claims 6
- 210000003169 central nervous system Anatomy 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 230000004064 dysfunction Effects 0.000 claims 6
- 230000036407 pain Effects 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 206010011224 Cough Diseases 0.000 claims 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 3
- 206010021143 Hypoxia Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 208000017119 Labyrinth disease Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 206010037660 Pyrexia Diseases 0.000 claims 3
- 206010046543 Urinary incontinence Diseases 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 230000017531 blood circulation Effects 0.000 claims 3
- 208000010643 digestive system disease Diseases 0.000 claims 3
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 3
- 230000007954 hypoxia Effects 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 230000007803 itching Effects 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 238000011321 prophylaxis Methods 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- 230000028016 temperature homeostasis Effects 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- UCRHYUZIOBPIAJ-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-(2,2,2-trifluoroethyl)amino]-n-[[3-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)N(CC(F)(F)F)CC(=O)NCC1=CC=CC(C=2C=CC(=CC=2)C(F)(F)F)=C1 UCRHYUZIOBPIAJ-UHFFFAOYSA-N 0.000 claims 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 2
- ILOMBJXOKNUNSS-QHCPKHFHSA-N (2s)-2-[(4-fluorophenyl)sulfonyl-methylamino]-3-methoxy-n-[[3-[4-(trifluoromethyl)phenyl]phenyl]methyl]propanamide Chemical compound CN([C@@H](COC)C(=O)NCC=1C=C(C=CC=1)C=1C=CC(=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 ILOMBJXOKNUNSS-QHCPKHFHSA-N 0.000 claims 1
- RATOEMFJNGGGOI-INIZCTEOSA-N (2s)-2-[(4-fluorophenyl)sulfonyl-methylamino]-n-[[3-[4-(trifluoromethyl)phenyl]phenyl]methyl]propanamide Chemical compound CN([C@@H](C)C(=O)NCC=1C=C(C=CC=1)C=1C=CC(=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 RATOEMFJNGGGOI-INIZCTEOSA-N 0.000 claims 1
- FZPUFNDTGDGLIL-INIZCTEOSA-N (2s)-2-[(4-fluorophenyl)sulfonyl-propan-2-ylamino]-n-[[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]methyl]propanamide Chemical compound O=C([C@H](C)N(C(C)C)S(=O)(=O)C=1C=CC(F)=CC=1)NCC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 FZPUFNDTGDGLIL-INIZCTEOSA-N 0.000 claims 1
- XLAWKWMNEURYQD-UHFFFAOYSA-N 2-[(2-cyanophenyl)sulfonyl-propan-2-ylamino]-n-[[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]methyl]acetamide Chemical compound C=1C=CC=C(C#N)C=1S(=O)(=O)N(C(C)C)CC(=O)NCC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 XLAWKWMNEURYQD-UHFFFAOYSA-N 0.000 claims 1
- MLPCZOSVDZQKIB-UHFFFAOYSA-N 2-[(3,4-difluorophenyl)sulfonyl-propan-2-ylamino]-n-[[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]methyl]acetamide Chemical compound C=1C=C(F)C(F)=CC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 MLPCZOSVDZQKIB-UHFFFAOYSA-N 0.000 claims 1
- QTPMUXAQZLMIHY-UHFFFAOYSA-N 2-[(3-fluorophenyl)sulfonyl-propan-2-ylamino]-n-[[2-[4-(trifluoromethyl)phenyl]pyridin-4-yl]methyl]acetamide Chemical compound C=1C=CC(F)=CC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(C=1)=CC=NC=1C1=CC=C(C(F)(F)F)C=C1 QTPMUXAQZLMIHY-UHFFFAOYSA-N 0.000 claims 1
- AWCCTKBSDFHYFY-UHFFFAOYSA-N 2-[(3-fluorophenyl)sulfonyl-propan-2-ylamino]-n-[[3-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=CC(F)=CC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(C=1)=CC=CC=1C1=CC=C(C(F)(F)F)C=C1 AWCCTKBSDFHYFY-UHFFFAOYSA-N 0.000 claims 1
- JSMNYRJPFDIXQP-UHFFFAOYSA-N 2-[(3-fluorophenyl)sulfonyl-propan-2-ylamino]-n-[[3-[5-(trifluoromethyl)pyridin-2-yl]phenyl]methyl]acetamide Chemical compound C=1C=CC(F)=CC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(C=1)=CC=CC=1C1=CC=C(C(F)(F)F)C=N1 JSMNYRJPFDIXQP-UHFFFAOYSA-N 0.000 claims 1
- MXDFLVYNUBAWTE-UHFFFAOYSA-N 2-[(3-fluorophenyl)sulfonyl-propan-2-ylamino]-n-[[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]methyl]acetamide Chemical compound C=1C=CC(F)=CC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 MXDFLVYNUBAWTE-UHFFFAOYSA-N 0.000 claims 1
- GOIZZFJCBUOBMG-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-(2-hydroxyethyl)amino]-n-[[3-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(CCO)CC(=O)NCC(C=1)=CC=CC=1C1=CC=C(C(F)(F)F)C=C1 GOIZZFJCBUOBMG-UHFFFAOYSA-N 0.000 claims 1
- ALZTUKGGWHQWRM-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-(2-hydroxyethyl)amino]-n-[[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(CCO)CC(=O)NCC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 ALZTUKGGWHQWRM-UHFFFAOYSA-N 0.000 claims 1
- BXWDPMQGDOKPGM-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-(2-hydroxypropyl)amino]-n-[[3-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(CC(O)C)CC(=O)NCC(C=1)=CC=CC=1C1=CC=C(C(F)(F)F)C=C1 BXWDPMQGDOKPGM-UHFFFAOYSA-N 0.000 claims 1
- WYRYPJQDSSMHIE-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-(oxetan-3-yl)amino]-n-[[3-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)N(C1COC1)CC(=O)NCC1=CC=CC(C=2C=CC(=CC=2)C(F)(F)F)=C1 WYRYPJQDSSMHIE-UHFFFAOYSA-N 0.000 claims 1
- SDONDHOTZMWQIG-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-methylamino]-2-methyl-n-[[3-[4-(trifluoromethyl)phenyl]phenyl]methyl]propanamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C)C(C)(C)C(=O)NCC(C=1)=CC=CC=1C1=CC=C(C(F)(F)F)C=C1 SDONDHOTZMWQIG-UHFFFAOYSA-N 0.000 claims 1
- NJZXMAAASRWNBE-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-methylamino]-n-[[2-fluoro-3-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C)CC(=O)NCC(C=1F)=CC=CC=1C1=CC=C(C(F)(F)F)C=C1 NJZXMAAASRWNBE-UHFFFAOYSA-N 0.000 claims 1
- AXIYRTUUSMILFQ-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-methylamino]-n-[[2-fluoro-5-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C)CC(=O)NCC(C(=CC=1)F)=CC=1C1=CC=C(C(F)(F)F)C=C1 AXIYRTUUSMILFQ-UHFFFAOYSA-N 0.000 claims 1
- WFZSBZSJRZUDDG-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-methylamino]-n-[[3-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C)CC(=O)NCC(C=1)=CC=CC=1C1=CC=C(C(F)(F)F)C=C1 WFZSBZSJRZUDDG-UHFFFAOYSA-N 0.000 claims 1
- ABNCWSACFKQHAW-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-methylamino]-n-[[3-[5-(trifluoromethyl)pyridin-2-yl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C)CC(=O)NCC(C=1)=CC=CC=1C1=CC=C(C(F)(F)F)C=N1 ABNCWSACFKQHAW-UHFFFAOYSA-N 0.000 claims 1
- RJYAKXKJNFJWEI-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-methylamino]-n-[[3-fluoro-5-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C)CC(=O)NCC(C=1)=CC(F)=CC=1C1=CC=C(C(F)(F)F)C=C1 RJYAKXKJNFJWEI-UHFFFAOYSA-N 0.000 claims 1
- GYOHILAZNFICEU-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-methylamino]-n-[[3-methoxy-5-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C(C=2C=CC(=CC=2)C(F)(F)F)=CC(OC)=CC=1CNC(=O)CN(C)S(=O)(=O)C1=CC=C(F)C=C1 GYOHILAZNFICEU-UHFFFAOYSA-N 0.000 claims 1
- KEVYRIWVVBGIAS-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-methylamino]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C)CC(=O)NCC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 KEVYRIWVVBGIAS-UHFFFAOYSA-N 0.000 claims 1
- RTVIZEVDNZWMIE-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-methylamino]-n-[[4-fluoro-3-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C)CC(=O)NCC(C=1)=CC=C(F)C=1C1=CC=C(C(F)(F)F)C=C1 RTVIZEVDNZWMIE-UHFFFAOYSA-N 0.000 claims 1
- DYYZHXGWNLBGIR-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-methylamino]-n-[[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C)CC(=O)NCC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 DYYZHXGWNLBGIR-UHFFFAOYSA-N 0.000 claims 1
- AOBWDCBQYPPPQA-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-propan-2-ylamino]-n-[[2-[2-(trifluoromethyl)pyrimidin-5-yl]pyridin-4-yl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(C=1)=CC=NC=1C1=CN=C(C(F)(F)F)N=C1 AOBWDCBQYPPPQA-UHFFFAOYSA-N 0.000 claims 1
- XWHIMEZMYXPMBY-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-propan-2-ylamino]-n-[[2-[6-(trifluoromethyl)pyridin-3-yl]pyridin-4-yl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(C=1)=CC=NC=1C1=CC=C(C(F)(F)F)N=C1 XWHIMEZMYXPMBY-UHFFFAOYSA-N 0.000 claims 1
- QLPZFKFWXTXDRI-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-propan-2-ylamino]-n-[[2-fluoro-5-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(C(=CC=1)F)=CC=1C1=CC=C(C(F)(F)F)C=C1 QLPZFKFWXTXDRI-UHFFFAOYSA-N 0.000 claims 1
- HPDAUJLDJCNNBQ-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-propan-2-ylamino]-n-[[3-[2-(trifluoromethyl)pyrimidin-5-yl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(C=1)=CC=CC=1C1=CN=C(C(F)(F)F)N=C1 HPDAUJLDJCNNBQ-UHFFFAOYSA-N 0.000 claims 1
- YTYYOIBTTMXWDO-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-propan-2-ylamino]-n-[[3-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(C=1)=CC=CC=1C1=CC=C(C(F)(F)F)C=C1 YTYYOIBTTMXWDO-UHFFFAOYSA-N 0.000 claims 1
- CQSLVXKYVQVIDY-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-propan-2-ylamino]-n-[[3-[5-(trifluoromethyl)pyrazin-2-yl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(C=1)=CC=CC=1C1=CN=C(C(F)(F)F)C=N1 CQSLVXKYVQVIDY-UHFFFAOYSA-N 0.000 claims 1
- XWFUFCQGVVCSIU-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-propan-2-ylamino]-n-[[3-[5-(trifluoromethyl)pyridin-2-yl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(C=1)=CC=CC=1C1=CC=C(C(F)(F)F)C=N1 XWFUFCQGVVCSIU-UHFFFAOYSA-N 0.000 claims 1
- BFBUALVHAJPHTR-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-propan-2-ylamino]-n-[[3-[6-(trifluoromethyl)pyridazin-3-yl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(C=1)=CC=CC=1C1=CC=C(C(F)(F)F)N=N1 BFBUALVHAJPHTR-UHFFFAOYSA-N 0.000 claims 1
- HSGHYPQZLXEXBI-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-propan-2-ylamino]-n-[[3-fluoro-5-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(C=1)=CC(F)=CC=1C1=CC=C(C(F)(F)F)C=C1 HSGHYPQZLXEXBI-UHFFFAOYSA-N 0.000 claims 1
- AAKXTOPANYWZSD-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-propan-2-ylamino]-n-[[3-fluoro-5-[6-(trifluoromethyl)pyridin-3-yl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(C=1)=CC(F)=CC=1C1=CC=C(C(F)(F)F)N=C1 AAKXTOPANYWZSD-UHFFFAOYSA-N 0.000 claims 1
- TVUIEJRGKKZQLR-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-propan-2-ylamino]-n-[[3-methoxy-5-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C(C=2C=CC(=CC=2)C(F)(F)F)=CC(OC)=CC=1CNC(=O)CN(C(C)C)S(=O)(=O)C1=CC=C(F)C=C1 TVUIEJRGKKZQLR-UHFFFAOYSA-N 0.000 claims 1
- PUTKJYONGLSXPT-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-propan-2-ylamino]-n-[[4-[3-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(C=C1)=CC=C1C1=CC=CC(C(F)(F)F)=C1 PUTKJYONGLSXPT-UHFFFAOYSA-N 0.000 claims 1
- VRAQUQDTKBWJSI-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-propan-2-ylamino]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 VRAQUQDTKBWJSI-UHFFFAOYSA-N 0.000 claims 1
- WAAVVXCLYNOPML-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-propan-2-ylamino]-n-[[4-fluoro-3-[2-(trifluoromethyl)pyrimidin-5-yl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(C=1)=CC=C(F)C=1C1=CN=C(C(F)(F)F)N=C1 WAAVVXCLYNOPML-UHFFFAOYSA-N 0.000 claims 1
- GJOLHRZDHHHTFH-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-propan-2-ylamino]-n-[[4-fluoro-3-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(C=1)=CC=C(F)C=1C1=CC=C(C(F)(F)F)C=C1 GJOLHRZDHHHTFH-UHFFFAOYSA-N 0.000 claims 1
- OZHDIPYLTFRSAE-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-propan-2-ylamino]-n-[[4-methoxy-3-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1=C(C=2C=CC(=CC=2)C(F)(F)F)C(OC)=CC=C1CNC(=O)CN(C(C)C)S(=O)(=O)C1=CC=C(F)C=C1 OZHDIPYLTFRSAE-UHFFFAOYSA-N 0.000 claims 1
- PXOGBLYEYIZXCT-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-propan-2-ylamino]-n-[[5-[4-(trifluoromethyl)phenyl]pyridin-3-yl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(C=1)=CN=CC=1C1=CC=C(C(F)(F)F)C=C1 PXOGBLYEYIZXCT-UHFFFAOYSA-N 0.000 claims 1
- FVONJMFNTQUATN-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-propan-2-ylamino]-n-[[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 FVONJMFNTQUATN-UHFFFAOYSA-N 0.000 claims 1
- USAKNJFJFIOYMS-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonyl-propan-2-ylamino]-n-[[6-[6-(trifluoromethyl)pyridin-3-yl]pyrimidin-4-yl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)N=C1 USAKNJFJFIOYMS-UHFFFAOYSA-N 0.000 claims 1
- VTZSSUCCIZXGEM-UHFFFAOYSA-N 2-[(5-chlorothiophen-2-yl)sulfonyl-propan-2-ylamino]-n-[[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]methyl]acetamide Chemical compound C=1C=C(Cl)SC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 VTZSSUCCIZXGEM-UHFFFAOYSA-N 0.000 claims 1
- HZZNBRZVAIKFDT-UHFFFAOYSA-N 2-[(5-chlorothiophen-2-yl)sulfonyl-propan-2-ylamino]-n-[[6-[6-(trifluoromethyl)pyridin-3-yl]pyrimidin-4-yl]methyl]acetamide Chemical compound C=1C=C(Cl)SC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)N=C1 HZZNBRZVAIKFDT-UHFFFAOYSA-N 0.000 claims 1
- ZZMOVSUGCOGGOT-UHFFFAOYSA-N 2-[(6-chloropyridin-3-yl)sulfonyl-propan-2-ylamino]-n-[[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]methyl]acetamide Chemical compound C=1C=C(Cl)N=CC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 ZZMOVSUGCOGGOT-UHFFFAOYSA-N 0.000 claims 1
- AHSFQEWHVNUGPW-UHFFFAOYSA-N 2-[benzenesulfonyl(propan-2-yl)amino]-n-[[3-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(C=1)=CC=CC=1C1=CC=C(C(F)(F)F)C=C1 AHSFQEWHVNUGPW-UHFFFAOYSA-N 0.000 claims 1
- YRNMBZKIYKFSQY-UHFFFAOYSA-N 2-[cyclopropyl-(4-fluorophenyl)sulfonylamino]-n-[[3-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)N(C1CC1)CC(=O)NCC1=CC=CC(C=2C=CC(=CC=2)C(F)(F)F)=C1 YRNMBZKIYKFSQY-UHFFFAOYSA-N 0.000 claims 1
- IRDJQRAHTSARMK-UHFFFAOYSA-N 2-[ethyl-(4-fluorophenyl)sulfonylamino]-n-[[2-fluoro-5-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(CC)CC(=O)NCC(C(=CC=1)F)=CC=1C1=CC=C(C(F)(F)F)C=C1 IRDJQRAHTSARMK-UHFFFAOYSA-N 0.000 claims 1
- LYWUDXIWQVKTDI-UHFFFAOYSA-N 2-[ethyl-(4-fluorophenyl)sulfonylamino]-n-[[3-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(CC)CC(=O)NCC(C=1)=CC=CC=1C1=CC=C(C(F)(F)F)C=C1 LYWUDXIWQVKTDI-UHFFFAOYSA-N 0.000 claims 1
- KCPPTTZEBSOPTM-UHFFFAOYSA-N 2-[ethyl-(4-fluorophenyl)sulfonylamino]-n-[[3-[5-(trifluoromethyl)pyridin-2-yl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(CC)CC(=O)NCC(C=1)=CC=CC=1C1=CC=C(C(F)(F)F)C=N1 KCPPTTZEBSOPTM-UHFFFAOYSA-N 0.000 claims 1
- FVBCLNYXKYKPOX-UHFFFAOYSA-N 2-[ethyl-(4-fluorophenyl)sulfonylamino]-n-[[3-fluoro-5-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(CC)CC(=O)NCC(C=1)=CC(F)=CC=1C1=CC=C(C(F)(F)F)C=C1 FVBCLNYXKYKPOX-UHFFFAOYSA-N 0.000 claims 1
- JEGKFUVXAUOAML-UHFFFAOYSA-N 2-[ethyl-(4-fluorophenyl)sulfonylamino]-n-[[3-methoxy-5-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(CC)CC(=O)NCC(C=1)=CC(OC)=CC=1C1=CC=C(C(F)(F)F)C=C1 JEGKFUVXAUOAML-UHFFFAOYSA-N 0.000 claims 1
- ZISCKJISSKRHDA-UHFFFAOYSA-N 2-[ethyl-(4-fluorophenyl)sulfonylamino]-n-[[4-[3-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(CC)CC(=O)NCC(C=C1)=CC=C1C1=CC=CC(C(F)(F)F)=C1 ZISCKJISSKRHDA-UHFFFAOYSA-N 0.000 claims 1
- FZHWPGGLTGMNBA-UHFFFAOYSA-N 2-[ethyl-(4-fluorophenyl)sulfonylamino]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(CC)CC(=O)NCC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 FZHWPGGLTGMNBA-UHFFFAOYSA-N 0.000 claims 1
- JUTUHDBQMRRODN-UHFFFAOYSA-N 2-[ethyl-(4-fluorophenyl)sulfonylamino]-n-[[4-fluoro-3-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(CC)CC(=O)NCC(C=1)=CC=C(F)C=1C1=CC=C(C(F)(F)F)C=C1 JUTUHDBQMRRODN-UHFFFAOYSA-N 0.000 claims 1
- XEADDEGNRRJKCQ-UHFFFAOYSA-N 2-[ethyl-(4-fluorophenyl)sulfonylamino]-n-[[4-methoxy-3-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(CC)CC(=O)NCC(C=1)=CC=C(OC)C=1C1=CC=C(C(F)(F)F)C=C1 XEADDEGNRRJKCQ-UHFFFAOYSA-N 0.000 claims 1
- GQJDJKRLOKTYAF-UHFFFAOYSA-N 2-[ethyl-(4-fluorophenyl)sulfonylamino]-n-[[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(CC)CC(=O)NCC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 GQJDJKRLOKTYAF-UHFFFAOYSA-N 0.000 claims 1
- MGBWFWWNFKGXIJ-UHFFFAOYSA-N 2-[methyl(thiophen-2-ylsulfonyl)amino]-n-[[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]methyl]acetamide Chemical compound C=1C=CSC=1S(=O)(=O)N(C)CC(=O)NCC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 MGBWFWWNFKGXIJ-UHFFFAOYSA-N 0.000 claims 1
- SLSAIIUVSJPXAS-UHFFFAOYSA-N 2-[propan-2-yl(pyrazin-2-ylsulfonyl)amino]-n-[[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]methyl]acetamide Chemical compound C=1N=CC=NC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 SLSAIIUVSJPXAS-UHFFFAOYSA-N 0.000 claims 1
- YIWAHWLSGOKBPT-UHFFFAOYSA-N 2-[propan-2-yl(pyridin-3-ylsulfonyl)amino]-n-[[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]methyl]acetamide Chemical compound C=1C=CN=CC=1S(=O)(=O)N(C(C)C)CC(=O)NCC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 YIWAHWLSGOKBPT-UHFFFAOYSA-N 0.000 claims 1
- BVJAWGTVKLWPEY-UHFFFAOYSA-N 2-[tert-butyl-(4-fluorophenyl)sulfonylamino]-n-[[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]methyl]acetamide Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)N(C(C)(C)C)CC(=O)NCC(N=CN=1)=CC=1C1=CC=C(C(F)(F)F)C=C1 BVJAWGTVKLWPEY-UHFFFAOYSA-N 0.000 claims 1
- JYFWEERHMRNIKW-UHFFFAOYSA-N 4-(trifluoromethyl)cyclohexene Chemical compound FC(F)(F)C1CCC=CC1 JYFWEERHMRNIKW-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000006387 trifluoromethyl pyridyl group Chemical group 0.000 claims 1
- 241001168730 Simo Species 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- 0 Cc1cc(*)ncc1 Chemical compound Cc1cc(*)ncc1 0.000 description 4
- LHXZPWCQXGTAER-UHFFFAOYSA-N Cc1ncnc(C(CC2)=CCC2C(F)(F)F)c1 Chemical compound Cc1ncnc(C(CC2)=CCC2C(F)(F)F)c1 LHXZPWCQXGTAER-UHFFFAOYSA-N 0.000 description 1
- WKPFWEOMEBYSLT-UHFFFAOYSA-N FC(c(nc1)ccc1-c1cc(S)ncn1)(F)F Chemical compound FC(c(nc1)ccc1-c1cc(S)ncn1)(F)F WKPFWEOMEBYSLT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/26—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Abstract
1. Соединение формулы (I):,где:X, Y, Z представляют собой, независимо друг от друга, С, СН или N;Rпредставляет собой незамещенный фенил, фенил, моно- или бизамещенный независимо галогеном или -CN, незамещенное пяти- или шестичленное гетероарильное кольцо или пяти- или шестичленное гетероарильное кольцо, замещенное низшим алкилом, галогеном, или галоалкилом;Rвыбран из группы, состоящей из метила, -CHCF, этила, гидрокси-этила, пропила, гидрокси-пропила, циклопропила, изопропила, метокси-этила, трет-бутила, оксетан-3-илметила или оксетанила;Rи Rкаждый независимо выбран из группы, состоящей из водорода; дейтерия; галоалкила; циклоалкила и низшего алкила, где указанный галоалкил, циклоалкил и низший алкил возможно замещены дейтерием, F, Cl, Br, гидроксилом или алкокси; или Rи R, взятые вместе с атомом углерода, к которому они присоединены, образуют 3-, 4-, 5- или 6-членный циклоалкил, возможно замещенный дейтерием, F, Cl, Br, гидроксилом или алкокси;Rпредставляет собой водород или низший алкил;Rпредставляет собой трифторметил-фенил, трифторметил-пиридинил, трифторметил-пиридазинил, трифторметил-пиримидинил, азетидино, пирролидино, циклоалкил, пиперидино, пирролидино-пиримидинил, гетероцикл, гетероцикл-пиримидинил, гетероцикл-пиридинил, гетероцикл-пиридазинил, гетероцикл-пиразинил, циклоалкил-пиримидинил, циклоалкил-пиридинил, циклоалкил-пиридазинил, циклоалкил-пиразинил, или трифторметил-пиразинил, где любой азетидинил, пирролидино, циклоалкил, гетероцикл, и пиперидино возможно замещены низшим алкилом, галогеном, трифторметилом, трифторметокси или трифторметилтио; иRпредставляет собой водород, галоген или алкокси,или его фармацевтически приемлемая соль.2. Соединение по п. 1, где X, Y и Z
Claims (39)
1. Соединение формулы (I):
где:
X, Y, Z представляют собой, независимо друг от друга, С, СН или N;
R1 представляет собой незамещенный фенил, фенил, моно- или бизамещенный независимо галогеном или -CN, незамещенное пяти- или шестичленное гетероарильное кольцо или пяти- или шестичленное гетероарильное кольцо, замещенное низшим алкилом, галогеном, или галоалкилом;
R2 выбран из группы, состоящей из метила, -CH2CF3, этила, гидрокси-этила, пропила, гидрокси-пропила, циклопропила, изопропила, метокси-этила, трет-бутила, оксетан-3-илметила или оксетанила;
R3 и R3′ каждый независимо выбран из группы, состоящей из водорода; дейтерия; галоалкила; циклоалкила и низшего алкила, где указанный галоалкил, циклоалкил и низший алкил возможно замещены дейтерием, F, Cl, Br, гидроксилом или алкокси; или R3 и R3′, взятые вместе с атомом углерода, к которому они присоединены, образуют 3-, 4-, 5- или 6-членный циклоалкил, возможно замещенный дейтерием, F, Cl, Br, гидроксилом или алкокси;
R4 представляет собой водород или низший алкил;
R5 представляет собой трифторметил-фенил, трифторметил-пиридинил, трифторметил-пиридазинил, трифторметил-пиримидинил, азетидино, пирролидино, циклоалкил, пиперидино, пирролидино-пиримидинил, гетероцикл, гетероцикл-пиримидинил, гетероцикл-пиридинил, гетероцикл-пиридазинил, гетероцикл-пиразинил, циклоалкил-пиримидинил, циклоалкил-пиридинил, циклоалкил-пиридазинил, циклоалкил-пиразинил, или трифторметил-пиразинил, где любой азетидинил, пирролидино, циклоалкил, гетероцикл, и пиперидино возможно замещены низшим алкилом, галогеном, трифторметилом, трифторметокси или трифторметилтио; и
R6 представляет собой водород, галоген или алкокси,
или его фармацевтически приемлемая соль.
2. Соединение по п. 1, где X, Y и Z независимо друг от друга представляют собой С или СН.
3. Соединение по п. 1, где один из X, Y или Z представляет собой N, а другие независимо друг от друга представляют собой С или СН.
4. Соединение по п. 1, где два из X, Y или Z представляют собой N, а другой представляет собой С или СН.
5. Соединение по п. 1, где R1 представляет собой незамещенный фенил, пиразинил, пиридинил или тиофенил.
6. Соединение по п. 1, где R1 представляет собой фенил, возможно замещенный циано, F или Cl, пиразинил, возможно замещенный F или Cl, пиридинил, возможно замещенный F или Cl, пиразол, возможно замещенный F или Cl, или тиенил, возможно замещенный F или Cl.
7. Соединение по п. 1, где R1 представляет собой фенил, замещенный F или Cl, пиразинил, замещенный F или Cl, пиридинил, замещенный F или Cl, или тиофенил, замещенный F или Cl.
8. Соединение по п. 1, где R2 представляет собой метил, -CH2CF3, этил, гидрокси-этил, 2-гидроксипропил, циклопропил, изопропил, 2-метоксиэтил, трет-бутил, метоксиметил, оксетан-3-илметил, 4-фторфенил, или 3-оксетанил.
9. Соединение по п. 1, где R3 и R3′ оба представляют собой водород.
10. Соединение по п. 1, где один из R3 или R3′ представляет собой водород, а другой представляет собой метил, трет-бутил, циклопропил, -СН2ОН или -СН2ОСН3.
11. Соединение по п. 1, где один из R3 или R3′ представляет собой водород, дейтерий или метил, а другой представляет собой водород, метил, изопропил, циклопропил, гидроксиметил, метоксиметил, или дейтерий; или R3 и R3′ взятые вместе с атомом углерода, к которому они присоединены, образуют 3-членный циклоалкил.
12. Соединение по п. 1, где R4 представляет собой водород.
13. Соединение по п. 1, где R4 представляет собой метил.
15. Соединение по п. 1, где R5 представляет собой трифторметил-фенил.
16. Соединение по п. 1, где R5 представляет 4-трифторметил-пиридинил, трифторметил-пиридазинил, трифторметил-пиримидинил или трифторметил-пиразинил.
17. Соединение по п. 1, где R5 представляет собой трифторметилфенил, 5-трифторметилпирид-2-ил, 6-трифторметилпирид-3-ил, 6-трифторметилпиридазин-3-ил, 2-трифторметилпиримидин-5-ил, 5-трифторметилпиразин-2-ил, пирролидино, циклопропил, 4,4-дифторпиперидино, 4-трифторметилпиперидино, 2-(2-метилпирролидино)пиримидин-5-ил, или 4-трифторметилциклогекс-1-ен.
18. Соединение по п. 1, где R6 представляет собой водород.
19. Соединение по п. 1, где R6 представляет собой F или метокси.
20. Соединение по п. 1, где R6 представляет собой галоген или алкокси.
22. Соединение по п. 1, где указанное соединение представляет собой:
2-[(4-фтор-бензолсульфонил)-метил-амино]-N-(4′-трифторметил-бифенил-3-илметил)-ацетамид;
(S)-2-[(4-фтор-бензолсульфонил)-метил-амино]-N-(4′-трифторметил-бифенил-3-илметил)-пропионамид;
(R)-2-[(4-фтор-бензолсульфонил)-метил-амино]-N-(4′-трифторметил-бифенил-3-илметил)-пропионамид;
(S)-2-[(4-фтор-бензолсульфонил)-метил-амино]-3-метил-N-(4′-трифторметил-бифенил-3-илметил)-бутирамид;
(R)-2-[(4-фтор-бензолсульфонил)-метил-амино]-3-метил-N-(4′-трифторметил-бифенил-3-илметил)-бутирамид;
2-[(4-фтор-бензолсульфонил)-метил-амино]-2-метил-N-(4′-трифторметил-бифенил-3-илметил)-пропионамид;
2-[(4-фтор-бензолсульфонил)-метил-амино]-N-(6-фтор-4′-трифторметил-бифенил-3-илметил)-ацетамид;
2-[(4-фтор-бензолсульфонил)-метил-амино]-N-(2-фтор-4′-трифторметил-бифенил-3-илметил)-ацетамид;
2-[(4-фтор-бензолсульфонил)-метил-амино]-N-(4′-трифторметил-бифенил-4-илметил)-ацетамид;
2-[(4-фтор-бензолсульфонил)-метил-амино]-N-(5-фтор-4′-трифторметил-бифенил-3-илметил)-ацетамид;
2-[(4-фтор-бензолсульфонил)-метил-амино]-N-(4-фтор-4′-трифторметил-бифенил-3-илметил)-ацетамид;
2-[(4-фтор-бензолсульфонил)-(2,2,2-трифтор-этил)-амино]-N-(4′-трифторметил-бифенил-3-илметил)-ацетамид;
2-[этил-(4-фтор-бензолсульфонил)-амино]-N-(6-фтор-4′-трифторметил-бифенил-3-илметил)-ацетамид;
2-[этил-(4-фтор-бензолсульфонил)-амино]-N-(5-фтор-4′-трифторметил-бифенил-3-илметил)-ацетамид;
2-[этил-(4-фтор-бензолсульфонил)-амино]-N-(4-фтор-4′-трифторметил-бифенил-3-илметил)-ацетамид;
2-[этил-(4-фтор-бензолсульфонил)-амино]-N-(4′-трифторметил-бифенил-4-илметил)-ацетамид;
2-[этил-(4-фтор-бензолсульфонил)-амино]-N-(3′-трифторметил-бифенил-4-илметил)-ацетамид;
2-[(4-фтор-бензолсульфонил)-(2-гидрокси-этил)-амино]-N-(4′-трифторметил-бифенил-3-илметил)-ацетамид;
2-[(4-фтор-бензолсульфонил)-(2-гидрокси-пропил)-амино]-N-(4′-трифторметил-бифенил-3-илметил)-ацетамид;
2-[(4-фтор-бензолсульфонил)-метил-амино]-N-[6-(4-трифторметил-фенил)-пиримидин-4-илметил]-ацетамид;
2-[циклопропил-(4-фтор-бензолсульфонил)-амино]-N-(4′-трифторметил-бифенил-3-илметил)-ацетамид;
2-[этил-(4-фтор-бензолсульфонил)-амино]-N-(4′-трифторметил-бифенил-3-илметил)-ацетамид;
2-[(5-хлор-тиофен-2-сульфонил)-метил-амино]-N-[6-(4-трифторметил-фенил)-пиримидин-4-илметил]-ацетамид;
2-[метил-(тиофен-2-сульфонил)-амино]-N-[6-(4-трифторметил-фенил)-пиримидин-4-илметил]-ацетамид;
2-[(4-фтор-бензолсульфонил)-изопропил-амино]-N-[6-(4-трифторметил-фенил)-пиримидин-4-илметил]-ацетамид;
2-[этил-(4-фтор-бензолсульфонил)-амино]-N-[6-(4-трифторметил-фенил)-пиримидин-4-илметил]-ацетамид;
2-[(4-фтор-бензолсульфонил)-(2-метокси-этил)-амино]-N-[6-(4-трифторметил-фенил)-пиримидин-4-илметил]-ацетамид;
2-[(4-фтор-бензолсульфонил)-(2-гидрокси-этил)-амино]-N-[6-(4-трифторметил-фенил)-пиримидин-4-илметил]-ацетамид;
2-[трет-бутил-(4-фтор-бензолсульфонил)-амино]-N-[6-(4-трифторметил-фенил)-пиримидин-4-илметил]-ацетамид;
(S)-2-[(4-фтор-бензолсульфонил)-изопропил-амино]-N-[6-(4-трифторметил-фенил)-пиримидин-4-илметил]-пропионамид;
2-[(4-фтор-бензолсульфонил)-изопропил-амино]-N-(4′-трифторметил-бифенил-4-илметил)-ацетамид;
2-[(4-фтор-бензолсульфонил)-изопропил-амино]-N-(3′-трифторметил-бифенил-4-илметил)-ацетамид;
2-[(4-фтор-бензолсульфонил)-изопропил-амино]-N-(6-фтор-4′-трифторметил-бифенил-3-илметил)-ацетамид;
2-[(4-фтор-бензолсульфонил)-изопропил-амино]-N-(5-фтор-4′-трифторметил-бифенил-3-илметил)-ацетамид;
2-[(4-фтор-бензолсульфонил)-изопропил-амино]-N-(4-фтор-4′-трифторметил-бифенил-3-илметил)-ацетамид;
(R)-2-[(4-фтор-бензолсульфонил)-метил-амино]-N-[6-(4-трифторметил-фенил)-пиримидин-4-илметил]-пропионамид;
2-[(4-фтор-бензолсульфонил)-изопропил-амино]-N-(4′-трифторметил-бифенил-3-илметил)-ацетамид;
2-[(4-фтор-бензолсульфонил)-изопропил-амино]-N-[3-(5-трифторметил-пиридин-2-ил)-бензил]-ацетамид;
2-[(4-фтор-бензолсульфонил)-метил-амино]-N-[3-(5-трифторметил-пиридин-2-ил)-бензил]-ацетамид;
2-[этил-(4-фтор-бензолсульфонил)-амино]-N-[3-(5-трифторметил-пиридин-2-ил)-бензил]-ацетамид;
2-[(4-фтор-бензолсульфонил)-метил-амино]-N-(5-метокси-4′-трифторметил-бифенил-3-илметил)-ацетамид;
2-[этил-(4-фтор-бензолсульфонил)-амино]-N-(5-метокси-4′-трифторметил-бифенил-3-илметил)-ацетамид;
2-[(4-фтор-бензолсульфонил)-изопропил-амино]-N-(5-метокси-4′-трифторметил-бифенил-3-илметил)-ацетамид;
2-[этил-(4-фтор-бензолсульфонил)-амино]-N-(6-метокси-4′-трифторметил-бифенил-3-илметил)-ацетамид;
2-[(4-фтор-бензолсульфонил)-изопропил-амино]-N-(6-метокси-4′-трифторметил-бифенил-3-илметил)-ацетамид;
2-[(3-фтор-бензолсульфонил)-изопропил-амино]-N-(4′-трифторметил-бифенил-3-илметил)-ацетамид;
2-[(3-фтор-бензолсульфонил)-изопропил-амино]-N-[6-(4-трифторметил-фенил)-пиримидин-4-илметил]-ацетамид;
2-[(3-фтор-бензолсульфонил)-изопропил-амино]-N-[3-(5-трифторметил-пиридин-2-ил)-бензил]-ацетамид;
2-[(4-фтор-бензолсульфонил)-метил-амино]-3-гидрокси-N-(4′-трифторметил-бифенил-3-илметил)-пропионамид;
(S)-2-[(4-фтор-бензолсульфонил)-метил-амино]-3-метокси-N-(4′-трифторметил-бифенил-3-илметил)-пропионамид;
2-(бензолсульфонил-изопропил-амино)-N-(4′-трифторметил-бифенил-3-илметил)-ацетамид;
2-[(4-фтор-бензолсульфонил)-оксетан-3-илметил-амино]-N-(4′-трифлуорон-3-илметил-амино]-N-(4′-трифторметил-бифенил-3-илметил)-ацетамид;
2-[(4-фтор-бензолсульфонил)-изопропил-амино]-N-(6-трифторметил-[3,4′]бипиридинил-2′-илметил)-ацетамид;
2-[Изопропил-(пиридин-3-сульфонил)-амино]-N-[6-(4-трифторметил-фенил)-пиримидин-4-илметил]-ацетамид;
2-[(4-фтор-бензолсульфонил)-изопропил-амино]-N-[5-(4-трифторметил-фенил)-пиридин-3-илметил]-ацетамид;
2-[(4-фтор-бензолсульфонил)-изопропил-амино]-N-(6′-трифторметил-[2,3′]бипиридинил-4-илметил)-ацетамид;
2-[(3-фтор-бензолсульфонил)-изопропил-амино]-N-[2-(4-трифторметил-фенил)-пиридин-4-илметил]-ацетамид;
2-[(4-фтор-бензолсульфонил)-оксетан-3-ил-амино]-N-(4′-трифторметил-бифенил-3-илметил)-ацетамид;
2-[(4-фтор-бензолсульфонил)-изопропил-амино]-N-[6-(6-трифторметил-пиридин-3-ил)-пиримидин-4-илметил]-ацетамид;
2-[(4-фтор-бензолсульфонил)-(2,2,2-трифтор-этил)-амино]-N-(4′-трифторметил-бифенил-3-илметил)-ацетамид;
2-[(4-фтор-бензолсульфонил)-изопропил-амино]-N-[3-фтор-5-(6-трифторметил-пиридин-3-ил)-бензил]-ацетамид;
2-[(6-хлор-пиридин-3-сульфонил)-изопропил-амино]-N-[6-(4-трифторметил-фенил)-пиримидин-4-илметил]-ацетамид;
2-[(2-циано-бензолсульфонил)-изопропил-амино]-N-[6-(4-трифторметил-фенил)-пиримидин-4-илметил]-ацетамид;
2-[(4-фтор-бензолсульфонил)-изопропил-амино]-N-[3-(6-трифторметил-пиридазин-3-ил)-бензил]-ацетамид;
2-[Изопропил-(пиразин-2-сульфонил)-амино]-N-[6-(4-трифторметил-фенил)-пиримидин-4-илметил]-ацетамид;
2-[(4-фтор-бензолсульфонил)-изопропил-амино]-N-[3-(2-трифторметил-пиримидин-5-ил)-бензил]-ацетамид;
2-[(3,4-дифтор-бензолсульфонил)-изопропил-амино]-N-[6-(4-трифторметил-фенил)-пиримидин-4-илметил]-ацетамид;
2-[(4-фтор-бензолсульфонил)-изопропил-амино]-N-[4-фтор-3-(2-трифторметил-пиримидин-5-ил)-бензил]-ацетамид;
2-[(4-фтор-бензолсульфонил)-изопропил-амино]-N-[3-(5-трифторметил-пиразин-2-ил)-бензил]-ацетамид;
2-[(6-хлор-пиридин-3-сульфонил)-изопропил-амино]-N-[3-(5-трифторметил-пиразин-2-ил)-бензил]-ацетамид;
2-[(6-хлор-пиридин-3-сульфонил)-изопропил-амино]-N-[3-(6-трифторметил-пиридазин-3-ил)-бензил]-ацетамид;
2-[(4-фтор-бензолсульфонил)-изопропил-амино]-N-[2-(2-трифторметил-пиримидин-5-ил)-пиридин-4-илметил]-ацетамид;
2-[(5-хлор-тиофен-2-сульфонил)-изопропил-амино]-N-[6-(4-трифторметил-фенил)-пиримидин-4-илметил]-ацетамид;
2-[(5-хлор-тиофен-2-сульфонил)-изопропил-амино]-N-[6-(6-трифторметил-пиридин-3-ил)-пиримидин-4-илметил]-ацетамид;
2-(4-фтор-N-(4-фторфенил)фенилсульфонамидо)-N-((6-(6-(трифторметил)пиридин-3-ил)пиримидин-4-ил)метил)ацетамид.
23. Соединение по п. 1, где указанное соединение представляет собой:
2-(4-фтор-N-изопропилфенилсульфониламидо)-N-(3-(пирролидин-1-ил)бензил)ацетамид;
N-(3-циклопропилбензил)-2-(4-фтор-N-изопропилфенилсульфониламидо)ацетамид;
R)-2-(4-фтор-N-изопропилфенилсульфониламидо)-N-(3-(2-(2-метилпирролидин-1-ил)пиримидин-5-ил)бензил)ацетамид;
(S)-2-(4-фтор-N-изопропилфенилсульфониламидо)-N-(3-(2-(2-метилпирролидин-1-ил)пиримидин-5-ил)бензил)ацетамид;
2-(4-фтор-N-изопропилфенилсульфониламидо)-N-((6-(4-(трифторметил)пиперидин-1-ил)пиримидин-4-ил)метил)ацетамид;
N-((6-(4,4-Дифторпиперидин-1-ил)пиримидин-4-ил)метил)-2-(4-фтор-N-изопропилфенилсульфониламидо)ацетамид;
2-(N-Изопропил-1-метил-1Н-пиразол-3-сульфонамидо)-N-((4′-(трифторметил)бифенил-3-ил)метил)ацетамид;
2,2-Дидейтерио-2-(4-фтор-N-изопропилфенилсульфониламидо)-N-((6-(6-(трифторметил)пиридин-3-ил)пиримидин-4-ил)метил)ацетамид;
1-(4-фтор-N-изопропилфенилсульфониламидо)-N-((6-(6-(трифторметил)пиридин-3-ил)пиримидин-4-ил)метил)цикпопропанкарбоксамид;
(6-(6-(трифторметил)пиридин-3-ил)пиримидин-4-ил)метил-2-(4-фтор-N-изопропилфенилсульфониламидо)ацетат; или
2-[N-(пропан-2-ил)(4-фторбензол)сульфониламидо]-N-([6-[4-(трифторметил)циклогекс-1-ен-1-ил]пиримидин-4-ил]метил)ацетамид;
или его соль.
24. Фармацевтическая композиция, содержащая соединение формулы (I) по любому из пп. 1-23 или его фармацевтически приемлемую соль, и фармацевтически приемлемый носитель, разбавитель или эксципиент.
25. Соединение формулы (I) по любому из пп. 1-23 или его фармацевтически приемлемая соль для применения в медицинском лечении.
26. Соединение формулы (I) по любому из пп. 1-23 или его фармацевтически приемлемая соль для лечения или профилактики респираторного заболевания.
27. Применение соединения формулы (I) по любому из пп. 1-23 или его фармацевтически приемлемой соли для получения лекарственного средства для лечения или профилактики респираторного заболевания.
28. Способ лечения респираторного заболевания у млекопитающих, содержащий введение соединения формулы (I) по любому из пп. 1-23 или его фармацевтически приемлемой соли млекопитающему.
29. Соединение формулы (I) по любому из пп. 1-23 или его фармацевтически приемлемая соль для модуляции активности TRPA1.
30. Соединение формулы (I) по любому из пп. 1-23 или его фармацевтически приемлемая соль для лечения или профилактики заболевания или состояния, опосредованного активностью TRPA1.
31. Соединение по п. 30, где заболевание или состояние представляет собой боль, зуд, воспалительное заболевание, расстройство внутреннего уха, лихорадку или другое нарушение терморегуляции, трахеобронхиальную дисфункцию или дисфункцию диафрагмы, заболевание желудочно-кишечного тракта, хроническое обструктивное заболевание легких, недержание мочи, или нарушение, связанное со снижением кровотока в ЦНС или ЦНС гипоксию.
32. Соединение по п. 31, где заболеванием или состоянием являются боль, артрит, зуд, кашель, астма, воспалительное заболевание кишечника или заболевание внутреннего уха.
33. Применение соединения формулы (I) по любому из пп. 1-23 или его фармацевтически приемлемой соли для получения лекарственного средства для лечения или профилактики заболевания или состояния, опосредованного активностью TRPA1.
34. Применение по п. 33, где заболевание или состояние представляет собой боль, зуд, воспалительное заболевание, расстройство внутреннего уха, лихорадку или другое нарушение терморегуляции, трахеобронхиальную дисфункцию или дисфункцию диафрагмы, заболевание желудочно-кишечного тракта, хроническое обструктивное заболевание легких, недержание мочи, или нарушение, связанное со снижением кровотока в ЦНС или ЦНС гипоксию.
35. Применение по п. 33, где заболеванием или состоянием являются боль, артрит, зуд, кашель, астма, воспалительное заболевание кишечника, или заболевание внутреннего уха.
36. Способ модуляции активности TRPA1, включающий взаимодействие TRPA1 с соединением формулы (I) по любому из пп. 1-23 или его соль.
37. Способ лечения заболевания или состояния, опосредованного активностью TRPA1 у млекопитающих, содержащий введение соединения формулы (I) по любому из пп. 1-23 или его фармацевтически приемлемой соли млекопитающему.
38. Способ по п. 37, где заболевание или состояние представляет собой боль, зуд, воспалительное заболевание, расстройство внутреннего уха, лихорадку или другое нарушение терморегуляции, трахеобронхиальную дисфункцию или дисфункцию диафрагмы, заболевание желудочно-кишечного тракта, хроническое обструктивное заболевание легких, недержание мочи, или нарушение, связанное со снижением кровотока в ЦНС или ЦНС гипоксию.
39. Способ по п. 37, где заболеванием или состоянием являются боль, артрит, зуд, кашель, астма, воспалительное заболевание кишечника или заболевание внутреннего уха.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261706286P | 2012-09-27 | 2012-09-27 | |
US61/706,286 | 2012-09-27 | ||
PCT/EP2013/070055 WO2014049047A1 (en) | 2012-09-27 | 2013-09-26 | Substituted sulfonamide compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2015113746A true RU2015113746A (ru) | 2016-11-20 |
Family
ID=49304910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015113746A RU2015113746A (ru) | 2012-09-27 | 2013-09-26 | Замещенные сульфонамиды |
Country Status (13)
Country | Link |
---|---|
US (1) | US9580411B2 (ru) |
EP (1) | EP2900642B1 (ru) |
JP (1) | JP6262743B2 (ru) |
KR (1) | KR20150061647A (ru) |
CN (1) | CN104684899B (ru) |
AR (1) | AR092684A1 (ru) |
BR (1) | BR112015006737A2 (ru) |
CA (1) | CA2885908A1 (ru) |
HK (1) | HK1210146A1 (ru) |
MX (1) | MX2015003565A (ru) |
RU (1) | RU2015113746A (ru) |
TW (1) | TW201418201A (ru) |
WO (1) | WO2014049047A1 (ru) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6182072B2 (ja) | 2012-01-17 | 2017-08-16 | Eaファーマ株式会社 | 複素環アミド誘導体及びそれを含有する医薬 |
EP2774919A1 (en) * | 2013-03-06 | 2014-09-10 | Pharmeste S.R.L. In Liquidazione | Novel sulfonamide TRPA1 receptor antagonists |
WO2017003862A1 (en) * | 2015-07-01 | 2017-01-05 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
EP3330266A1 (en) * | 2015-07-29 | 2018-06-06 | Ea Pharma Co., Ltd. | Cyclopropane derivative and drug containing same |
WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
WO2017064068A1 (en) | 2015-10-14 | 2017-04-20 | Almirall, S.A. | New trpa1 antagonists |
TW202222786A (zh) | 2016-02-01 | 2022-06-16 | 美商百歐克斯製藥公司 | 苯并吡唑化合物及其類似物 |
CA3012812A1 (en) * | 2016-02-05 | 2017-08-10 | Ea Pharma Co., Ltd. | Heterocyclic sulfonamide derivative and medicine containing same |
EP3487849A1 (en) * | 2016-07-20 | 2019-05-29 | H. Hoffnabb-La Roche Ag | Sulfonylcycloalkyl carboxamide compounds as trpa1 modulators |
EP3487853B1 (en) * | 2016-07-20 | 2022-06-08 | F. Hoffmann-La Roche AG | Bicyclic proline compounds |
WO2018029288A1 (en) * | 2016-08-12 | 2018-02-15 | F. Hoffmann-La Roche Ag | Sulfonyl pyridyl trp inhibitors |
CN109843855B (zh) * | 2016-11-08 | 2021-06-25 | 正大天晴药业集团股份有限公司 | 作为cccDNA抑制剂的磺酰胺类化合物 |
CN111848552B (zh) * | 2019-04-28 | 2023-12-19 | 南京富润凯德生物医药有限公司 | 一种3-(取代苯基)氧杂环丁烷-3-羧酸及其中间体的制备方法及应用 |
FR3114235A1 (fr) | 2020-09-18 | 2022-03-25 | Université Grenoble Alpes | Inhibition du canal trpa1 astrocytaire comme nouvelle cible therapeutique neuroprotectrice dans les phases prodromales de la maladie d’alzheimer |
JP2024503262A (ja) * | 2020-12-25 | 2024-01-25 | エムティックスバイオ カンパニ- リミテッド | 新規なアミノアルカン酸にビフェニル基を導入した誘導体化合物およびそれを含む抗炎症用組成物 |
IT202100015098A1 (it) | 2021-06-09 | 2022-12-09 | Flonext S R L | Composto antagonista del canale trpa1 per uso in patologie degenerative della retina |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
WO1994002178A1 (en) | 1992-07-27 | 1994-02-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Targeting of liposomes to the blood-brain barrier |
MXPA01008606A (es) * | 1999-02-26 | 2003-05-05 | Merck & Co Inc | Compuestos de sulfonamida novedosos y uso de los mismos. |
US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
AU2001286930A1 (en) | 2000-08-30 | 2002-03-13 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
WO2003009815A2 (en) | 2001-07-25 | 2003-02-06 | Biomarin Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
CA2507762C (en) | 2002-12-03 | 2013-02-05 | Blanchette Rockefeller Neurosciences Institute | Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier |
EP1663239A4 (en) | 2003-09-10 | 2008-07-23 | Cedars Sinai Medical Center | KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER |
TW200817319A (en) | 2006-08-10 | 2008-04-16 | Astellas Pharma Inc | Sulfonamide compound or salt thereof |
WO2010141805A1 (en) * | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heterocyclic amides as modulators of trpa1 |
US8637529B2 (en) * | 2010-06-11 | 2014-01-28 | AbbYie Inc. | Pyrazolo[3,4-d]pyrimidine compounds |
CA2865962A1 (en) * | 2012-02-29 | 2013-09-06 | Institute For Hepatitis And Virus Research | Inhibitors of hepatitis b virus covalently closed circular dna formation and their method of use |
CA2879256A1 (en) * | 2012-10-16 | 2014-04-24 | F. Hoffmann-La Roche Ag | Substituted carbamate compounds and their use as transient receptor potential (trp) channel antagonists |
EP2774919A1 (en) * | 2013-03-06 | 2014-09-10 | Pharmeste S.R.L. In Liquidazione | Novel sulfonamide TRPA1 receptor antagonists |
-
2013
- 2013-09-26 EP EP13773658.3A patent/EP2900642B1/en not_active Not-in-force
- 2013-09-26 JP JP2015533579A patent/JP6262743B2/ja not_active Expired - Fee Related
- 2013-09-26 TW TW102134873A patent/TW201418201A/zh unknown
- 2013-09-26 KR KR1020157010667A patent/KR20150061647A/ko not_active Application Discontinuation
- 2013-09-26 WO PCT/EP2013/070055 patent/WO2014049047A1/en active Application Filing
- 2013-09-26 CN CN201380050416.8A patent/CN104684899B/zh not_active Expired - Fee Related
- 2013-09-26 CA CA2885908A patent/CA2885908A1/en not_active Abandoned
- 2013-09-26 BR BR112015006737A patent/BR112015006737A2/pt not_active IP Right Cessation
- 2013-09-26 AR ARP130103449A patent/AR092684A1/es unknown
- 2013-09-26 MX MX2015003565A patent/MX2015003565A/es unknown
- 2013-09-26 RU RU2015113746A patent/RU2015113746A/ru not_active Application Discontinuation
-
2015
- 2015-03-27 US US14/671,643 patent/US9580411B2/en active Active
- 2015-11-03 HK HK15110828.0A patent/HK1210146A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN104684899B (zh) | 2017-07-04 |
US9580411B2 (en) | 2017-02-28 |
BR112015006737A2 (pt) | 2017-07-04 |
CN104684899A (zh) | 2015-06-03 |
HK1210146A1 (en) | 2016-04-15 |
MX2015003565A (es) | 2015-06-22 |
JP2015535836A (ja) | 2015-12-17 |
KR20150061647A (ko) | 2015-06-04 |
EP2900642B1 (en) | 2018-02-28 |
CA2885908A1 (en) | 2014-04-03 |
US20150197509A1 (en) | 2015-07-16 |
TW201418201A (zh) | 2014-05-16 |
WO2014049047A1 (en) | 2014-04-03 |
AR092684A1 (es) | 2015-04-29 |
JP6262743B2 (ja) | 2018-01-17 |
EP2900642A1 (en) | 2015-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2015113746A (ru) | Замещенные сульфонамиды | |
JP2017505794A5 (ru) | ||
RU2004117887A (ru) | Ариланилиновые агонисты бета2 адренергических рецепторов | |
JP2004504301A5 (ru) | ||
RU2009101911A (ru) | Производные пиридина и пиразина в качестве ингибиторов mnk-киназы | |
RU2016115868A (ru) | Замещенные гетероциклические сульфонамидные соединения, полезные в качестве модуляторов trpa 1 | |
JP2015524837A5 (ru) | ||
RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
RU2013114352A (ru) | Азабензотиазолы, композиции и способы применения | |
JP2005509024A5 (ru) | ||
JP2009500372A5 (ru) | ||
IL264982B (en) | Hetero(aryl)cyclopropylamine compounds as lsd1 inhibitors | |
RU2018131766A (ru) | 6-гетероциклил-4-морфолин-4-илпиридин-2-оны, пригодные для лечения рака и диабета | |
JP2009526072A5 (ru) | ||
RU2015142383A (ru) | Новейшие антагонисты trpa1-рецепторов | |
RU2016105511A (ru) | Сульфонамиды в качестве молдуляторов натриевых каналов | |
JP2016535000A5 (ru) | ||
JP2018522823A5 (ru) | ||
RU2014148316A (ru) | Производные 1-фенил-2-пиридинил-алкиловых спиртов в качестве ингибиторов фосфодиэстеразы | |
RU2009116670A (ru) | Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина | |
HRP20201193T1 (hr) | Policiklični spojevi kao inhibitori brutonove tirozin kinaze | |
CA2601508A1 (en) | Cyclopropanecarboxamide derivatives | |
JP2019505595A5 (ru) | ||
JP2017537948A5 (ru) | ||
RU2010110640A (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180112 |